Copyright: ©Author(s) 2026.
World J Immunol. Nov 20, 2026; 16(3): 125225
Published online Nov 20, 2026. doi: 10.5411/wji.125225
Published online Nov 20, 2026. doi: 10.5411/wji.125225
Table 1 Modulation of metainflammation in the treatment of metabolic liver diseases
| Drugs | Clinical trials | Phases | Mechanisms/aims | Ref. |
| HEC88473, a dual agonist of GLP-1 and FGF21 | NCT05943886 | 1 | Improvement in glycemic control and lipid metabolism. Reduction in hepatic fat fraction | [98] |
| Pegozafermin | NCT04048135; NCT04929483; NCT06419374 | 1/2; 2; 3 | Improvement in glycemic control, serum lipids, and liver injury and fibrosis | [99,100] |
| Lanifibranor, a PPAR pan-agonist | NCT03459079 | 2 | Improvement in glucose and lipid metabolism. Inhibition of hepatic and peripheral insulin resistance | [101] |
| Chiglitazar, a PPAR pan-agonist | NCT05193916 | 2 | Improvement of liver injury. Reduction in liver fat content | [102] |
| Probiotics: LL001, LH001, and PPKID7 | NCT04555434 | 1/2 | Improvement in liver injury. Body weight loss. Reduction in total cholesterol | [103] |
| Three consecutive FMTs | NCT04465032 | 4 | Change of gut microbiota alpha diversity | [104] |
| Fonte essenziale | NCT07211113 | Not applicable | Reduction of intestinal permeability. Inhibition of systemic inflammation and oxidative stress | [105] |
| Dietary supplementation with dihydromyricetin, vitamin C, E, and choline | NCT05052515 | Not applicable | Antioxidant activity and glycemic control. Improvement in sugar and lipid metabolism | [106,107] |
- Citation: Zhang CY, Yang M. Metabolic inflammation in metabolic dysfunction-associated steatotic liver disease. World J Immunol 2026; 16(3): 125225
- URL: https://www.wjgnet.com/2219-2824/full/v16/i3/125225.htm
- DOI: https://dx.doi.org/10.5411/wji.125225